SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 7.85% Stake in Orthofix Medical Inc.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a beneficial ownership of 7.85% in Orthofix Medical Inc.'s common stock as of December 31, 2024.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the 'Reporting Persons,' beneficially own 3,000,000 shares of Orthofix Medical Inc.'s common stock.
• This ownership represents 7.85% of the total outstanding shares of Orthofix Medical Inc.
• The percentage is calculated based on 38,214,187 shares outstanding as of November 1, 2024, as reported in the Issuer's Form 10-Q.
• Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
• Both Armistice Capital, LLC and Steven Boyd share voting and dispositive power over all 3,000,000 shares.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating an update to a previously reported beneficial ownership.
• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Orthofix Medical Inc.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as a significant institutional stake by a reputable investment firm can be seen as a vote of confidence in the company, even if it's a passive investment.

Positives

• The disclosure of a significant 7.85% stake by an institutional investor like Armistice Capital and its managing member, Steven Boyd, can be viewed as a vote of confidence in Orthofix Medical Inc.'s long-term prospects.
• The holding is explicitly stated to be for ordinary course of business, not for control, which suggests a passive investment strategy focused on value.

Risks

• The document explicitly states that the shares were not acquired or held for the purpose of changing or influencing the control of the issuer, mitigating concerns about potential activist investor actions.

Future Outlook

This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or strategic direction.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing reflects a routine disclosure of significant institutional ownership in a publicly traded medical device company. Such filings provide transparency into the ownership structure and can indicate investor confidence or strategic positioning within the healthcare sector.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant institutional holder, which can influence investor perception and potentially provide stability to the stock by indicating a long-term holder.

Key Dates

Keywords

Orthofix Medical Inc., Armistice Capital, Steven Boyd, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Medical Devices, Orthopedics